Home | Welcome to Contract Pharma   
Last Updated Wednesday, October 1 2014
Print

Biogen Idec 3Q



Published October 23, 2007
Biogen Idec

3Q Revenues: $789 million (+12%)

3Q Earnings: $119 million (-24%)

YTD Revenues: $2.3 billion (+15%)

YTD Earnings: $437 million (+301%)

Comments: Avonex sales leveled off, up 2% to $455 million, while BI's share of Rituxan revenues rose 15% to $235 million. During the quarter, the company's named Paul Clancy to the role of chief financial officer. Two months later, BI's board authorized management to look for a buyer for the company.


blog comments powered by Disqus
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On